Different effects of biological drugs in rheumatoid arthritis

Fabiola Atzeni, Maurizio Benucci, Salvatore Sallì, Sara Bongiovanni, Laura Boccassini, Piercarlo Sarzi-Puttini

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

Biological drugs have brought new hope to patients with rheumatoid arthritis (RA) in whom previously existing treatments could not control inflammation, joint destruction, or the progression of disability. The five currently available TNF blockers are approved for treating RA patients, but they have different structures, morphology, pharmacokinetic properties, and activity.Randomised clinical trials (RCTs) have shown that they improve the signs and symptoms of both early and long-standing RA and other inflammatory arthritides, prevent radiographic progression, and improve the patients' health-related quality of life. However, they are more effective in combination with methotrexate (MTX) than alone. Combined treatment is generally well tolerated, and seems to be relatively safe in the short term, as confirmed by RCTs, long-term observational studies and in clinical practice. Patients who fail to respond or develop adverse effects - when treated with one anti-TNF agent can be successfully treated with a second TNF antagonist. However, in the case of primary failure, it is possible that biological agents with a different mechanism of action may be more successful. Tocilizumab alone or in combination with MTX is more effective than MTX monotherapy in reducing disease activity over 24. weeks. Abatacept is well tolerated and retains its efficacy over time, as does rituximab in non-responders to other anti-TNF drugs. Finally, although these drugs improve the quality of life of RA patients, they considerably increase direct medical costs.

Original languageEnglish
Pages (from-to)575-579
Number of pages5
JournalAutoimmunity Reviews
Volume12
Issue number5
DOIs
Publication statusPublished - Mar 2013

Fingerprint

Rheumatoid Arthritis
Methotrexate
Pharmaceutical Preparations
Randomized Controlled Trials
Quality of Life
Biological Factors
Signs and Symptoms
Arthritis
Observational Studies
Pharmacokinetics
Joints
Inflammation
Costs and Cost Analysis
Therapeutics

Keywords

  • Abatacept
  • Anti-IL6
  • Anti-TNF agents
  • Biological drugs
  • Rituximab

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Atzeni, F., Benucci, M., Sallì, S., Bongiovanni, S., Boccassini, L., & Sarzi-Puttini, P. (2013). Different effects of biological drugs in rheumatoid arthritis. Autoimmunity Reviews, 12(5), 575-579. https://doi.org/10.1016/j.autrev.2012.10.020

Different effects of biological drugs in rheumatoid arthritis. / Atzeni, Fabiola; Benucci, Maurizio; Sallì, Salvatore; Bongiovanni, Sara; Boccassini, Laura; Sarzi-Puttini, Piercarlo.

In: Autoimmunity Reviews, Vol. 12, No. 5, 03.2013, p. 575-579.

Research output: Contribution to journalArticle

Atzeni, F, Benucci, M, Sallì, S, Bongiovanni, S, Boccassini, L & Sarzi-Puttini, P 2013, 'Different effects of biological drugs in rheumatoid arthritis', Autoimmunity Reviews, vol. 12, no. 5, pp. 575-579. https://doi.org/10.1016/j.autrev.2012.10.020
Atzeni F, Benucci M, Sallì S, Bongiovanni S, Boccassini L, Sarzi-Puttini P. Different effects of biological drugs in rheumatoid arthritis. Autoimmunity Reviews. 2013 Mar;12(5):575-579. https://doi.org/10.1016/j.autrev.2012.10.020
Atzeni, Fabiola ; Benucci, Maurizio ; Sallì, Salvatore ; Bongiovanni, Sara ; Boccassini, Laura ; Sarzi-Puttini, Piercarlo. / Different effects of biological drugs in rheumatoid arthritis. In: Autoimmunity Reviews. 2013 ; Vol. 12, No. 5. pp. 575-579.
@article{3ef8557c33b74d4f8fdad1916fc31ecb,
title = "Different effects of biological drugs in rheumatoid arthritis",
abstract = "Biological drugs have brought new hope to patients with rheumatoid arthritis (RA) in whom previously existing treatments could not control inflammation, joint destruction, or the progression of disability. The five currently available TNF blockers are approved for treating RA patients, but they have different structures, morphology, pharmacokinetic properties, and activity.Randomised clinical trials (RCTs) have shown that they improve the signs and symptoms of both early and long-standing RA and other inflammatory arthritides, prevent radiographic progression, and improve the patients' health-related quality of life. However, they are more effective in combination with methotrexate (MTX) than alone. Combined treatment is generally well tolerated, and seems to be relatively safe in the short term, as confirmed by RCTs, long-term observational studies and in clinical practice. Patients who fail to respond or develop adverse effects - when treated with one anti-TNF agent can be successfully treated with a second TNF antagonist. However, in the case of primary failure, it is possible that biological agents with a different mechanism of action may be more successful. Tocilizumab alone or in combination with MTX is more effective than MTX monotherapy in reducing disease activity over 24. weeks. Abatacept is well tolerated and retains its efficacy over time, as does rituximab in non-responders to other anti-TNF drugs. Finally, although these drugs improve the quality of life of RA patients, they considerably increase direct medical costs.",
keywords = "Abatacept, Anti-IL6, Anti-TNF agents, Biological drugs, Rituximab",
author = "Fabiola Atzeni and Maurizio Benucci and Salvatore Sall{\`i} and Sara Bongiovanni and Laura Boccassini and Piercarlo Sarzi-Puttini",
year = "2013",
month = "3",
doi = "10.1016/j.autrev.2012.10.020",
language = "English",
volume = "12",
pages = "575--579",
journal = "Autoimmunity Reviews",
issn = "1568-9972",
publisher = "Elsevier",
number = "5",

}

TY - JOUR

T1 - Different effects of biological drugs in rheumatoid arthritis

AU - Atzeni, Fabiola

AU - Benucci, Maurizio

AU - Sallì, Salvatore

AU - Bongiovanni, Sara

AU - Boccassini, Laura

AU - Sarzi-Puttini, Piercarlo

PY - 2013/3

Y1 - 2013/3

N2 - Biological drugs have brought new hope to patients with rheumatoid arthritis (RA) in whom previously existing treatments could not control inflammation, joint destruction, or the progression of disability. The five currently available TNF blockers are approved for treating RA patients, but they have different structures, morphology, pharmacokinetic properties, and activity.Randomised clinical trials (RCTs) have shown that they improve the signs and symptoms of both early and long-standing RA and other inflammatory arthritides, prevent radiographic progression, and improve the patients' health-related quality of life. However, they are more effective in combination with methotrexate (MTX) than alone. Combined treatment is generally well tolerated, and seems to be relatively safe in the short term, as confirmed by RCTs, long-term observational studies and in clinical practice. Patients who fail to respond or develop adverse effects - when treated with one anti-TNF agent can be successfully treated with a second TNF antagonist. However, in the case of primary failure, it is possible that biological agents with a different mechanism of action may be more successful. Tocilizumab alone or in combination with MTX is more effective than MTX monotherapy in reducing disease activity over 24. weeks. Abatacept is well tolerated and retains its efficacy over time, as does rituximab in non-responders to other anti-TNF drugs. Finally, although these drugs improve the quality of life of RA patients, they considerably increase direct medical costs.

AB - Biological drugs have brought new hope to patients with rheumatoid arthritis (RA) in whom previously existing treatments could not control inflammation, joint destruction, or the progression of disability. The five currently available TNF blockers are approved for treating RA patients, but they have different structures, morphology, pharmacokinetic properties, and activity.Randomised clinical trials (RCTs) have shown that they improve the signs and symptoms of both early and long-standing RA and other inflammatory arthritides, prevent radiographic progression, and improve the patients' health-related quality of life. However, they are more effective in combination with methotrexate (MTX) than alone. Combined treatment is generally well tolerated, and seems to be relatively safe in the short term, as confirmed by RCTs, long-term observational studies and in clinical practice. Patients who fail to respond or develop adverse effects - when treated with one anti-TNF agent can be successfully treated with a second TNF antagonist. However, in the case of primary failure, it is possible that biological agents with a different mechanism of action may be more successful. Tocilizumab alone or in combination with MTX is more effective than MTX monotherapy in reducing disease activity over 24. weeks. Abatacept is well tolerated and retains its efficacy over time, as does rituximab in non-responders to other anti-TNF drugs. Finally, although these drugs improve the quality of life of RA patients, they considerably increase direct medical costs.

KW - Abatacept

KW - Anti-IL6

KW - Anti-TNF agents

KW - Biological drugs

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=84875278357&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875278357&partnerID=8YFLogxK

U2 - 10.1016/j.autrev.2012.10.020

DO - 10.1016/j.autrev.2012.10.020

M3 - Article

VL - 12

SP - 575

EP - 579

JO - Autoimmunity Reviews

JF - Autoimmunity Reviews

SN - 1568-9972

IS - 5

ER -